offline
Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology
– Data showed improvement in both heartburn and regurgitation symptoms and further demonstrated the role of bile acid in refractory gastroesophageal reflux disease (GERD) –
– IW-3718 is currently in two Phase III trials; top line data targeted for second half of 2020 –
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Gastroenterology - the official journal of the American Gastroenterological Association (AGA) - has published data from its Phase IIb clinical trial evaluating IW-3718 in adults with refractory gastroesophageal reflux disease (GERD). The data demonstrated that IW-3718 1500 mg given twice daily (BID) plus a proton pump inhibitor (PPI) significantly reduced heartburn severity and reduced the frequency of regurgitation – two of the most bothersome and frequently reported symptoms of GERD1 – compared to a PPI alone. Additionally, more than 50 percent of patients treated with IW-3718 1500 mg BID plus a PPI reported a clinically meaningful reduction in heartburn severity. IW-3718 was well-tolerated in the trial; the most common adverse event reported overall was constipation. Data from this study were previously presented at Digestive Disease Week® (DDW) in Washington, D.C., June 2018.
The publication can be accessed at the following link: https://www.gastrojournal.org/article/S0016-5085(20)30242-0/fulltext
https://finance.yahoo.com/news/ironwood-...00759.html
– Data showed improvement in both heartburn and regurgitation symptoms and further demonstrated the role of bile acid in refractory gastroesophageal reflux disease (GERD) –
– IW-3718 is currently in two Phase III trials; top line data targeted for second half of 2020 –
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that Gastroenterology - the official journal of the American Gastroenterological Association (AGA) - has published data from its Phase IIb clinical trial evaluating IW-3718 in adults with refractory gastroesophageal reflux disease (GERD). The data demonstrated that IW-3718 1500 mg given twice daily (BID) plus a proton pump inhibitor (PPI) significantly reduced heartburn severity and reduced the frequency of regurgitation – two of the most bothersome and frequently reported symptoms of GERD1 – compared to a PPI alone. Additionally, more than 50 percent of patients treated with IW-3718 1500 mg BID plus a PPI reported a clinically meaningful reduction in heartburn severity. IW-3718 was well-tolerated in the trial; the most common adverse event reported overall was constipation. Data from this study were previously presented at Digestive Disease Week® (DDW) in Washington, D.C., June 2018.
The publication can be accessed at the following link: https://www.gastrojournal.org/article/S0016-5085(20)30242-0/fulltext
https://finance.yahoo.com/news/ironwood-...00759.html
__________________
